Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

104 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-25

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of mutations and therapy response; whether ctDNA detection can be used to predict the risk of ovarian cancer recurrence; and the characteristics of immune repertoire before and after treatment in patients with ovarian cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration

NCT06564428

Ovarian Neoplasms

RECRUITING

Inherited Susceptible Genes Among Epithelial Ovarian Cancer

NCT03015376

Ovarian Neoplasm Epithelial Hereditary Breast and Ovarian Cancer Syndrome

UNKNOWN

Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.

NCT03155451

Epithelial Ovarian Cancer

COMPLETED

New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence

NCT05410028

Ovarian Cancer

RECRUITING

A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

NCT04651920

Epithelial Ovarian Cancer Chinese Homologous Recombination Deficiency +4 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

100 OC cases with available matched tumor DNA and plasma will be collected. All patients will be treated according to clinical guidelines, and receive circulating tumor DNA (ctDNA) liquid biopsy at the time of diagnosis, at mid treatment, at the end of treatment and during follow-up. The study will be ended when the patients have progressive disease (PD) or reach the longest follow-up time (2 years).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who have not received treatment including radiotherapy, chemotherapy, and surgery.
* Expected to achieve satisfactory tumor cytoreductive surgery.
* Estimated lifetime is more than 3 months.
* Understand the research plan and voluntarily participate in the study, sign the informed consent form.
* Ability to collect specimens from each time point and provide corresponding clinical information.

Exclusion Criteria

* Patients who will receive new adjuvant therapy.
* Patients who have other primary cancer.
* Pregnant or breast-feeding woman.
* Patients with severe mental illness.
* Patients achieve unsatisfactory tumor cytoreductive surgery.
* Patients who voluntarily withdraw for any reason.
* Patients who cannot complete the research plan.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No